این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Blood and Cancer، جلد ۲، شماره ۱، صفحات ۳۳-۳۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Evaluation of Anthracycline Effects on NT-ProBNP Plasma Level in Children with Malignancy
چکیده انگلیسی مقاله Background: NT-proBNP is a marker that is released from ventricles in response to pressure and volume overload. Raised plasma level of NT-proBNP is seen in ventricular dysfunction, ventricular muscular mass reduction or ventricular ischemia. Anthracyclines are widely used in treatment of pediatric cancer but their use is associated with cardiotoxicity which increases mortality and morbidity. We measured the plasma levels of NT-proBNP to determine whether it might serve as a simple prognostic indicator of anthracycline-induced cardiotoxicity and to estimate the toxic levels of anthracyclines in children with malignancy treated with anthracycline containing regimens in Tehran’s Mofid hospital. Materials and Methods: This study was performed as a before and after clinical trial. Twenty-nine pediatric patients less than fifteen years old with newly diagnosed cancer were enrolled in this study. All patients received anthracycline-containing chemotherapy with 120 to 150 mg/m² in accumulative dose. Serial measurements of plasma NT-proBNP levels and echocardiographies were taken before onset of chemotherapy, simultaneous with accumulative dose of 120 to 150 mg/m² and two weeks after that dose. Results: Plasma levels of NT-proBNP were within normal limits before treatment and increased significantly after the mentioned accumulative dose (P=0.002) in 26 patients out of 29. All patients had normal echocardiograms and none developed heart failure during the two-year period of the study.Conclusion: NT-proBNP levels increases significantly after 120 to 150 mg/m² as accumulative dose in a subset of pediatric cancer patients. This increase is not associated with echocardiographic or clinical evidence of cardiac dysfunction. Longer follow-up of these patients is necessary to determine whether NT-proBNP can be used as an early and prognostic marker for anthracycline-induced cardiotoxicity and whether 120 to 150 mg/m² as accumulative dose of anthracycline is a safe dose or not.
کلیدواژه‌های انگلیسی مقاله NT-proBNP, Child, Malignancy, Cardiac dysfunction
نویسندگان مقاله کورش گودرزی پور | kourosh goudarzi pour
department of pediatric hematology oncology, shahid beheshti medical un iversity, mofid hospital, tehran, iran.


شاهین شمسیان | shahin shamsian
department of pediatric hematology oncology, shahid beheshti medical un iversity, mofid hospital, tehran, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (Shahid beheshti university of medical sciences)

fatemé وزیری | fatemé vaziri
department of pediatric cardiology, shahid behesh ti medical university, mofid hospital, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (Shahid beheshti university of medical sciences)

رکسانا آقاخانی | roxana aghakhani
department of pathology, shahid beheshti medical university, mofid hospital, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (Shahid beheshti university of medical sciences)

محمد تقی ارزانیان | mohammad taghi arzanian
department of pediatric hematology oncology, shahid beheshti medical un iversity, mofid hospital, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (Shahid beheshti university of medical sciences)

نشانی اینترنتی http://www.ijbc.ir/browse.php?a_code=A-10-2-166&slc_lang=en&sid=en
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده 1
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات